596 related articles for article (PubMed ID: 33596848)
1. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
[TBL] [Abstract][Full Text] [Related]
2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
3. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
[TBL] [Abstract][Full Text] [Related]
4. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok J; Lee M; Kim DK; Kim JS; Jhun BW; Jo KW; Jeon D; Lee T; Lee JY; Park JS; Lee SH; Kang YA; Lee JK; Kwak N; Ahn JH; Shim TS; Kim SY; Kim S; Kim K; Seok KH; Yoon S; Kim YR; Kim J; Yim D; Hahn S; Cho SN; Yim JJ;
Lancet; 2022 Oct; 400(10362):1522-1530. PubMed ID: 36522208
[TBL] [Abstract][Full Text] [Related]
5. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
Gao J; Gao M; Du J; Pang Y; Mao G; Lounis N; Bakare N; Jiang Y; Zhan Y; Liu Y; Li L;
Trials; 2024 Apr; 25(1):227. PubMed ID: 38561815
[TBL] [Abstract][Full Text] [Related]
6. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Patil SB; Tamirat M; Khazhidinov K; Ardizzoni E; Atger M; Austin A; Baudin E; Bekhit M; Bektasov S; Berikova E; Bonnet M; Caboclo R; Chaudhry M; Chavan V; Cloez S; Coit J; Coutisson S; Dakenova Z; De Jong BC; Delifer C; Demaisons S; Do JM; Dos Santos Tozzi D; Ducher V; Ferlazzo G; Gouillou M; Khan U; Kunda M; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moreau M; Moschioni M; Nahid P; Osso E; Oyewusi L; Panda S; Pâquet A; Thuong Huu P; Pichon L; Rich ML; Rupasinghe P; Salahuddin N; Sanchez Garavito E; Seung KJ; Velásquez GE; Vallet M; Varaine F; Yuya-Septoh FJ; Mitnick CD; Guglielmetti L
Trials; 2023 Nov; 24(1):773. PubMed ID: 38037119
[TBL] [Abstract][Full Text] [Related]
7. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
8. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
[TBL] [Abstract][Full Text] [Related]
9. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
[TBL] [Abstract][Full Text] [Related]
10. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
[TBL] [Abstract][Full Text] [Related]
11. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
Chiang CY; Lin CJ
Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
[TBL] [Abstract][Full Text] [Related]
12. Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Walsh KF; Souroutzidis A; Vilbrun SC; Peeples M; Joissaint G; Delva S; Widmann P; Royal G; Pry J; Bang H; Pape JW; Koenig SP
Am J Trop Med Hyg; 2019 Feb; 100(2):392-398. PubMed ID: 30594266
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing.
Chen X; He G; Lin S; Wang S; Sun F; Chen J; Zhang W
mSphere; 2020 Dec; 5(6):. PubMed ID: 33361124
[TBL] [Abstract][Full Text] [Related]
14. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
15. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
16. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
17. Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.
Dudnyk A; Hempel M; Lytvyniuk O; Liudkevych H; Matsera V; Nikitchenko T; Blyzniuk S; Molina-Moya B; Preyer R; Domínguez J
Ther Adv Respir Dis; 2024; 18():17534666241249841. PubMed ID: 38817020
[TBL] [Abstract][Full Text] [Related]
18. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
Ziganshina LE; Titarenko AF; Davies GR
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD004795. PubMed ID: 23744519
[TBL] [Abstract][Full Text] [Related]
19. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
Juma SP; Maro A; Pholwat S; Mpagama SG; Gratz J; Liyoyo A; Houpt ER; Kibiki GS; Mmbaga BT; Heysell SK
BMC Infect Dis; 2019 Feb; 19(1):129. PubMed ID: 30732572
[TBL] [Abstract][Full Text] [Related]
20. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]